The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )

UICC announces global coalition to increase access to essential cancer medicines...

Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patient...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio,...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Vaccinations in myeloma patients including for COVID-19

Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria

Vaccinations in myeloma patients including for COVID-19 ( Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax fo...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, N...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...

Prof Evangelos Terpos - University of Athens, Athens, Greece

Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )

More from ecancer